Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
| Descriptor ID |
D011993
|
| MeSH Number(s) |
D12.776.828.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 3 | 4 |
| 2003 | 3 | 2 | 5 |
| 2004 | 3 | 7 | 10 |
| 2005 | 1 | 8 | 9 |
| 2006 | 0 | 8 | 8 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 1 | 3 |
| 2009 | 0 | 3 | 3 |
| 2010 | 3 | 2 | 5 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 4 | 6 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 3 | 5 |
| 2016 | 4 | 7 | 11 |
| 2017 | 25 | 26 | 51 |
| 2018 | 25 | 21 | 46 |
| 2019 | 10 | 11 | 21 |
| 2020 | 2 | 6 | 8 |
| 2021 | 1 | 8 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
Evolutionary loss of inflammasomes in the Carnivora and implications for the carriage of zoonotic infections. Cell Rep. 2021 08 24; 36(8):109614.
-
[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs]. Biol Aujourdhui. 2021; 215(1-2):25-43.
-
Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19. Front Immunol. 2021; 12:679841.
-
Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production. Sci Adv. 2021 08; 7(32).
-
A Novel Use of Romiplostim for SARS-CoV-2-induced Thrombocytopenia. J Pediatr Hematol Oncol. 2021 08 01; 43(6):e788-e790.
-
Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1. Muscle Nerve. 2021 10; 64(4):487-490.
-
Construction of Fluorescent Immunosensor Quenchbody to Detect His-Tagged Recombinant Proteins Produced in Bioprocess. Sensors (Basel). 2021 Jul 22; 21(15).
-
Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial. Chin Med J (Engl). 2021 07 22; 134(16):1967-1976.
-
CyDisCo production of functional recombinant SARS-CoV-2 spike receptor binding domain. Protein Sci. 2021 09; 30(9):1983-1990.
-
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science. 2021 08 27; 373(6558):991-998.